

# KIR2DS3 Antibody (C-term) Blocking peptide

Synthetic peptide Catalog # BP5763b

### **Specification**

### KIR2DS3 Antibody (C-term) Blocking peptide - Product Information

Primary Accession <u>Q14952</u> Other Accession <u>NP 036445.1</u>

# KIR2DS3 Antibody (C-term) Blocking peptide - Additional Information

**Gene ID 3808** 

#### **Other Names**

Killer cell immunoglobulin-like receptor 2DS3, MHC class I NK cell receptor, Natural killer-associated transcript 7, NKAT-7, KIR2DS3, NKAT7

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

# KIR2DS3 Antibody (C-term) Blocking peptide - Protein Information

Name KIR2DS3 (HGNC:6335)

**Synonyms NKAT7** 

## **Function**

Receptor on natural killer (NK) cells for HLA-C alleles. Does not inhibit the activity of NK cells.

## **Cellular Location**

Cell membrane; Single-pass type I membrane protein

# KIR2DS3 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

#### • Blocking Peptides

### KIR2DS3 Antibody (C-term) Blocking peptide - Images



# KIR2DS3 Antibody (C-term) Blocking peptide - Background

Killer cell immunoglobulin-like receptors (KIRs) aretransmembrane glycoproteins expressed by natural killer cells and subsets of T cells. The KIR genes are polymorphic and highlyhomologous and they are found in a cluster on chromosome 19q13.4within the 1 Mb leukocyte receptor complex (LRC). The gene contentof the KIR gene cluster varies among haplotypes, although several framework genes are found in all haplotypes (KIR3DL3, KIR3DP1,KIR3DL4, KIR3DL2). The KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain. KIR proteins with the long cytoplasmic domain transduce inhibitory signals uponligand binding via an immune tyrosine-based inhibitory motif (ITIM), while KIR proteins with the short cytoplasmic domain lack the ITIM motif and instead associate with the TYRO protein tyrosinekinase binding protein to transduce activating signals. The ligands for several KIR proteins are subsets of HLA class I molecules; thus, KIR proteins are thought to play an important role inregulation of the immune response.

### KIR2DS3 Antibody (C-term) Blocking peptide - References

Valiante, N.M., et al. Immunity 7(6):739-751(1997)Bottino, C., et al. Eur. J. Immunol. 26(8):1816-1824(1996)Dohring, C., et al. Immunogenetics 44(3):227-230(1996)Wagtmann, N., et al. Immunity 2(5):439-449(1995)